Medication info
MCPOLMIN Extended-Release Tablet 25/100/1000 mg (Empagliflozin, Sitagliptin, Metformin)

MCPOLMIN Extended-Release Tablet 25/100/1000 mg (Empagliflozin, Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletSitagliptin Phosphate Hydrate›128.5mg / 1 tabletEmpagliflozin L-Proline›31.38mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Blue double convex oval extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500915 · Approved 2025.04.16 · Insurance code 643309750

Summary

Main use
Improves blood glucose control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening, with gradual dose titration. Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets together once daily. For patients whose blood glucose is not adequately controlled with metformin and sitagliptin, the starting dose of this medicine should be empagliflozin 10 mg, sitagliptin 100 mg, and the metformin hydrochloride dose the patient was taking, or an appropriate dose therapeutically equivalent to it. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin to this medicine, use the dose of each component that the patient was previously taking. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Improves blood glucose control in adults with type 2 diabetes mellitus

View approved original text

This medication is used to improve blood glucose control in adult patients with type 2 diabetes and is best used in conjunction with diet and exercise therapies. Empagliflozin, sitagliptin, and metformin work together to effectively control blood sugar levels. As a result, blood glucose levels are stabilized, aiding in diabetes management. If taken safely and consistently, positive effects on blood glucose control can be expected.

How to take

Adult dose

For antidiabetic therapy, the recommended dose of this medicine is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily dose of each component: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal in the evening, with gradual dose titration. Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets together once daily. For patients whose blood glucose is not adequately controlled with metformin and sitagliptin, the starting dose of this medicine should be empagliflozin 10 mg, sitagliptin 100 mg, and the metformin hydrochloride dose the patient was taking, or an appropriate dose therapeutically equivalent to it. If empagliflozin 10 mg is tolerated and additional glycemic control is needed, the dose of empagliflozin may be increased to 25 mg. For patients switching from combination therapy with empagliflozin, sitagliptin, and metformin to this medicine, use the dose of each component that the patient was previously taking. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication contains sitagliptin, empagliflozin, and metformin, which help improve blood glucose control. Sitagliptin may rarely cause serious allergic reactions, so if symptoms like skin rash or difficulty breathing occur, usage must be stopped immediately and a doctor should be consulted. Furthermore, acute pancreatitis may occur, so if symptoms such as abdominal pain or vomiting appear, healthcare personnel should be informed immediately. Metformin may rarely cause a serious side effect known as lactic acidosis, so if symptoms like sudden fatigue, muscle pain, or difficulty breathing appear, a hospital visit is required immediately. This medication should not be used in patients with type 1 diabetes, severe renal impairment, acute heart failure, or severe infections. Especially in cases of impaired renal function, kidney function tests should be performed before administration, and if necessary, dose adjustments or cessation of therapy should be considered. Additionally, if surgery or iodinated contrast examinations are planned, discontinuation of this medication should occur 48 hours prior to the examination and it should only be resumed once renal function has been confirmed to be normal. There is a risk of hypoglycemia with this medication, so blood glucose changes should be closely monitored when taken alongside insulin or sulfonylureas. Infections may occur during treatment, particularly urinary tract infections or genital infections, so prompt treatment should be sought if relevant symptoms arise. Dehydration or hypotension may pose risks due to fluid loss, so patients with dehydration symptoms or the elderly should exercise caution. Patients with liver dysfunction should avoid this medication, and excessive alcohol consumption should also be avoided. Regular blood tests and kidney function assessments are crucial while taking this medication to detect and manage adverse reactions early. If blisters or severe joint pain occur, it is important to inform a doctor immediately as such symptoms may necessitate drug discontinuation. Caution is advised when driving or operating machinery due to the risk of hypoglycemia, particularly if used with insulin or sulfonylureas.

Side effects

Hypersensitivity, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, influenza, nasopharyngitis, anal abscess, perforated appendicitis, cervicitis, coronavirus infection, otitis media, periodontitis, dental abscess, vaginitis, indigestion, abdominal pain, upper abdominal pain, diarrhea, dry mouth, alcoholic gastritis, erosive gastritis, hematemesis, hemorrhoids, nausea, chest pain, asthenia, fatigue, increased blood sugar, weight loss, increased serum creatine phosphokinase, eyelid spasm, diabetic retinopathy, keratitis, vitreous hemorrhage, transitional cell carcinoma of the bladder, prostate cancer, renal cell carcinoma, right angle block, left ventricular hypertrophy, hyperglycemia, hypoglycemia, vulvar pruritus, diaphoresis, dermatitis, orthostatic dizziness, bile duct obstruction, forearm fracture, headache, insomnia, urinary frequency, sleep apnea syndrome, removal of artificial fixation device, vomiting, change in bowel habits, colitis, dental caries, enteritis, otitis externa, cataract, borderline glaucoma, endocrine ophthalmopathy, arthralgia, lumbar spinal stenosis, spinal canal stenosis, cough, eosinophilic bronchitis, oropharyngeal pain, bruise, metatarsal fracture, radiculopathy, thalamic stroke, breast mass, keloid scar, rash, aortic aneurysm, hypotension, ventricular extrasystole, gill pouch, vaginismus, vulvovaginitis, balanitis, urinary tract infection, perineal necrosis, vascular stent stenosis, vascular stent thrombosis, pneumonia, pulmonary tuberculosis, sepsis, subcutaneous abscess, tubo-ovarian abscess, vestibular neuronitis, acute pyelonephritis, meningitis, chronic otitis media, peritonsillar abscess, acute kidney injury, ureterolithiasis, cervicitis, hyponatremia, diabetic foot, low back pain, glaucoma, pathological myopia, retinal detachment, retinal vein occlusion, large retinal detachment, limb injury, road traffic accident, spleen injury, sternum fracture, angina, Prinzmetal angina, coronary artery disease, deep vein thrombosis, acute cholecystitis, autoimmune hepatitis, cholelithiasis, hepatitis, ear pain, orthostatic vertigo, anemia, lymphadenopathy, hypothyroidism, thyroid nodule, taste impairment, nausea, vomiting, diarrhea, abdominal pain, anorexia, erythema, pruritus, urticaria, rash, severe and disabling arthralgia, blistering resembling pemphigus, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, hypoglycemia, reduced fluid volume, dehydration, hypotension, hypovolemia, orthostatic hypotension, syncope, increased serum creatinine, decreased glomerular filtration rate, vaginismus, vulvovaginitis, balanitis, genital infection, increased urination, urinary tract infection, fluid volume loss, headache, anxiety, depression, sleep disorder, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain storage temperatures between 1 and 30 degrees Celsius at room temperature. This will help preserve the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Blue double convex oval extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.